8Sapience

Disclaimer : Do your own due diligence. Not a buy/sell/hold recommendation. Use Smart Quant Analyzer - alpha.8sapience.ai If you like this and need similar analysis for any other companies - just comment/dm. Like/Repost if it helps you in some way

Pipeline strength: - ₹18.36B Q4 sales (+32% QoQ), ₹62.77B FY26 pipeline, 2-3 new city entries planned. - Strong momentum as shown by recent 1 month - volume growth - India's structural realty growth + SOBHA's execution = alpha potential.

🧵 SOBHA's 93% profit surge in FY25 validates 3 strategic bets that could redefine India's realty sector. Here's why this isn't just another quarterly beat - it's a blueprint for the next decade Three strategic bets validated with hard numbers. Lets dive in 👉 screenshots from alpha.8sapience.ai

@money_theory Do try out alpha.8sapience.ai

@8Sapience Screenshots look decent 🙌

Suven Life Sciences surged 140.66% over the past year despite widening losses reaching ₹439.45 crore in Q4 FY25 And market capitalization of ₹5,109 crore at 47.4x book value contrasts sharply with a -84.6% ROE So, why stock is soaring new heights? Let's try to decode the Biotech Valuation Paradox... screenshots from : alpha.8sapience.ai

What is meant by recent announcement by Dr. Reddy’s to Co-Develop Biosimilar Candidate for global markets... source: nsearchives.nseindia.com/corporate/DRRE… Deal Structure & Financials Partnership: Dr. Reddy's + Alvotech for AVT03 (denosumab biosimilar) Investment: ₹560 crores ($67mn) - ₹317 crores upfront + ₹243 crores milestones Revenue Share: Sales-based payments to Alvotech Rights: Exclusive US + Semi-exclusive Europe/UK markets Market Opportunity TAM: $3.7bn (FY25) → $5.59bn (FY29) at 13% CAGR Reference Product: Prolia/Xgeva ($5.3bn revenue in 2021) Indication: Osteoporosis (postmenopausal women) + cancer bone complications Strategic Rationale - Portfolio Upgrade: Shift from low-margin generics to high-value biosimilars US Market Entry: Exclusive access to world's largest pharma market - De-risked Model: Alvotech handles R&D/manufacturing; DRL leverages existing commercial infrastructure Recent Developments - Regulatory: FDA BLA accepted, EMA application filed - Clinical: Positive PK study results completed - Timeline: Commercial launch expected FY26-27 Financial Impact Revenue Potential: - ₹2,000-3,000 crores annually post-launch - Margin Accretion: Biosimilars command 30-40% higher margins vs generics - Payback: 3-4 years on ₹560 crore investment Key Risks - Regulatory approval delays - Pricing pressure from competition - Market penetration challenges Valuation & Recommendation - Current biosimilar portfolio contributes <10% to revenues. - Successful denosumab launch could add 15-20% to topline by FY28. screenshot from - alpha.8sapience.ai Disclaimer: Educational, DYOR, Consult Advisor

@thebigbulldeals screenshots from alpha.8sapience.ai ⚠️ Educational content only. Not investment advice. DYOR & consult advisors.

Bharat Electronics #BEL Bags fresh defence and allied orders worth ₹537 Cr, reinforcing its position in the defence sector.

Disclaimer : Do your own due diligence. Not a buy/sell/hold recommendation. Use Smart Quant Analyzer - alpha.8sapience.ai If you like this and need similar analysis for any other companies - just comment/dm. Like/Repost if it helps you in some way

7/7 🚀 Bottom Line: Nuvama = The only Indian stock giving you: ✅ Wealth management (sticky revenues) ✅ Asset services (institutional scale) ✅ International expansion (NRI wealth) ✅ AI advantage (cost efficiency) Key catalyst: Singapore operations FY26 ⚠️ Educational content only. Not investment advice. DYOR & consult advisors.

While Nifty corrected 19% in H2 FY25, NUVAMA's client assets GREW 24% YoY to ₹4.3L Cr. - 65% PAT growth, 500bps margin expansion ==> isn't just surviving, it's THRIVING in tough markets. Trading at 26.8x vs 360 One's 35.5x before NRI goldmine hits... Thread 👇

Disclaimer : Do your own due diligence. Not a buy/sell/hold recommendation. Use Smart Quant Analyzer - alpha.8sapience.ai If you like this and need similar analysis for any other companies - just comment/dm. Like/Repost if it helps you in some way

What looks like bull case ? - 2 approved drugs by 2030 - $3B market cap via licensing deals - 500% upside from current levels Do comment/dm on this with your point of view.